Investor Overview
News
- Elanco Announces Agreement to Acquire Kindred BiosciencesJune 16, 2021 6:30 AM EDT
- Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by ParvovirusJune 2, 2021 8:31 AM EDT
- Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XIMay 25, 2021 8:42 AM EDT
Events
- Tuesday, June 8, 2021 from 1:30 PM to 1:55 PM EDT
- Wednesday, June 2, 2021 from 11:00 AM to 11:25 AM EDT
- Tuesday, May 11, 2021 4:30 PM EDT
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
Investor Overview
KindredBio is focused on bringing innovative biologics and technologies to veterinary medicine to address unmet clinical needs and provide benefits to pets.
Stock Information
News
Elanco Announces Agreement to Acquire Kindred Biosciences
June 16, 2021
Bolt-on Acquisition Accelerates Elanco’s Expansion in Pet Health Elanco to host...
Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus
June 2, 2021
- Study demonstrated 100% survival in dogs treated with KIND-030, even in the abs...
Kindred Biosciences to Present at Stifel 2021 Virtual Jaws & Paws Conference and LD Micro Invitational XI
May 25, 2021
SAN FRANCISCO , May 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...